Royalty Pharma (RPRX) Dividends Paid - Common Growth (1y) (2020 - 2026)
Royalty Pharma (RPRX) Dividends Paid - Common Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Div. Paid (Common) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 4.26% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Royalty Pharma | 25.71 Bn | 25.10 Bn | - | -25.92% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -25.92% |
| Dec 31, 2025 | 29.60% |
| Sep 30, 2025 | 10.52% |
| Jun 30, 2025 | 25.82% |
| Mar 31, 2025 | 68.17% |
| Dec 31, 2024 | 28.42% |
| Sep 30, 2024 | -0.33% |
| Jun 30, 2024 | 0.50% |
| Mar 31, 2024 | -4.14% |
| Dec 31, 2023 | -26.13% |
| Sep 30, 2023 | -19.42% |
| Jun 30, 2023 | -19.30% |
| Mar 31, 2023 | -3.25% |
| Dec 31, 2022 | 114.40% |
| Sep 30, 2022 | -69.21% |
| Jun 30, 2022 | -66.37% |
| Mar 31, 2022 | -72.55% |
| Dec 31, 2021 | 19.91% |
| Sep 30, 2021 | 7.80% |
| Jun 30, 2021 | -8.67% |